{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:56:45Z","timestamp":1787698605863,"version":"build-2784847793"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ijrobp.2020.09.054","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T17:28:48Z","timestamp":1608658128000},"page":"237-248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response"],"prefix":"10.1016","volume":"110","author":[{"given":"Kyle","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Mavroidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Royce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron D.","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Sapareto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan C.","family":"Sheets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald B.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issam","family":"El Naqa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Yorke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimm","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2020.09.054_bib1","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2008.18.6486","article-title":"Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function","volume":"27","author":"Chen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000484616","article-title":"Urinary incontinence, patient satisfaction, and decisional regret after prostate cancer treatment: A French national study","volume":"100","author":"Albkri","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3857\/roj.2017.02026","article-title":"Stereotactic radiotherapy of the prostate: Fractionation and utilization in the United States","volume":"35","author":"Weiner","year":"2017","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib4","first-page":"354","article-title":"Hypofractionated radiation therapy for localized prostate cancer: An ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib6","first-page":"2015","article-title":"Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer","volume":"34","author":"Yoshida","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","article-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","volume":"76","author":"Szymanski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1748-717X-8-171","article-title":"Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams:\u00a0Preliminary report of a phase II study","volume":"8","author":"Alongi","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00066-010-2179-1","article-title":"Definition of the CTV prostate in CT and MRI by using CT-MRI image fusion in IMRT planning for prostate cancer","volume":"187","author":"Hentschel","year":"2011","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijrobp.2003.11.022","article-title":"Localization of neurovascular bundles on pelvic CT and evaluation of radiation dose to structures putatively involved in erectile dysfunction after prostate brachytherapy","volume":"59","author":"Wright","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib11","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/j.prro.2019.06.009","article-title":"Comparison of motion-insensitive T2-weighted MRI pulse sequences for visualization of the prostatic urethra during MR simulation","volume":"9","author":"Zakian","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib12","article-title":"Simple diagrammatic method to delineate male urethra in prostate cancer radiotherapy: An MRI based approach","volume":"89","author":"Kataria","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.radonc.2013.03.022","article-title":"Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: Toxicity, biochemical, and pathological outcomes","volume":"107","author":"Loblaw","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib14","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","article-title":"Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer","volume":"29","author":"Boike","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"10.1016\/j.ijrobp.2020.09.054_bib15","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1016\/j.ijrobp.2009.02.090","article-title":"Radiation dose-volume effects of the urinary bladder","volume":"76","author":"Viswanathan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib17","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: A Radiation Therapy Oncology Group consensus panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2018.01.014","article-title":"ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer","volume":"127","author":"Salembier","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib19","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ijrobp.2015.03.021","article-title":"Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy","volume":"92","author":"Harris","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2490-13-49","article-title":"A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy","volume":"13","author":"Bolzicco","year":"2013","journal-title":"BMC Urol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.radonc.2014.06.009","article-title":"Dosimetric and patient correlates of quality of life after prostate stereotactic ablative radiotherapy","volume":"112","author":"Elias","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fonc.2014.00301","article-title":"Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study","volume":"4","author":"Katz","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fonc.2014.00312","article-title":"SBRT for the primary treatment of localized prostate cancer: The effect of Gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN risk stratification guidelines","volume":"4","author":"Bernetich","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13014-015-0351-6","article-title":"Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer","volume":"10","author":"Gurka","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.prro.2015.01.006","article-title":"Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Gomez","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib27","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/j.prro.2015.02.001","article-title":"Dose-volume analysis and the temporal nature of toxicity with stereotactic body radiation therapy for prostate cancer","volume":"5","author":"Seymour","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.radonc.2016.08.012","article-title":"Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy","volume":"121","author":"Qi","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3109\/0284186X.2015.1037011","article-title":"Late urinary toxicity modeling after stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer","volume":"55","author":"Kole","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib30","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.radonc.2017.03.006","article-title":"Stereotactic ablative radiotherapy in the treatment of low and intermediate risk prostate cancer: Is there an optimal dose?","volume":"123","author":"Helou","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib31","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/j.prro.2016.07.004","article-title":"Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer","volume":"7","author":"Zhang","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.prro.2017.08.004","article-title":"A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life","volume":"8","author":"Jackson","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijrobp.2014.03.012","article-title":"Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer","volume":"89","author":"Kim","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib34","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ijrobp.2015.12.010","article-title":"Predictive parameters of symptomatic hematochezia following 5-fraction gantry-based SABR in prostate cancer","volume":"94","author":"Musunuru","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib35","first-page":"1007","article-title":"Cyberknife radioablation of prostate cancer: Preliminary results for 400 patients","volume":"18","author":"Miszczyk","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib36","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijrobp.2009.07.1748","article-title":"Sexual function after stereotactic body radiotherapy for prostate cancer: Results of a prospective clinical trial","volume":"78","author":"Wiegner","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib37","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/1748-717X-8-256","article-title":"Potency preservation following stereotactic body radiation therapy for prostate cancer","volume":"8","author":"Obayomi-Davies","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/bju.13962","article-title":"Erectile function after stereotactic body radiotherapy for localized prostate cancer","volume":"121","author":"Dess","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib39","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.prro.2015.02.010","article-title":"Increased radiation dose heterogeneity within the prostate predisposes to urethral strictures in patients receiving moderately hypofractionated prostate radiation therapy","volume":"5","author":"McDonald","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.radonc.2015.12.020","article-title":"Dose-escalation of five-fraction SABR in prostate cancer: Toxicity comparison of two prospective trials","volume":"118","author":"Musunuru","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1118\/1.598063","article-title":"Reporting and analyzing dose distributions: A concept of equivalent uniform dose","volume":"24","author":"Niemierko","year":"1997","journal-title":"Med Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib42","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-06-0039","article-title":"Polymorphisms in genes related to oxidative stress (CAT, MnSOD, MPO, and eNOS) and acute toxicities from radiation therapy following lumpectomy for breast cancer","volume":"12","author":"Ahn","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib43","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.urology.2013.01.047","article-title":"Toxicity after external beam radiotherapy for prostate cancer: An analysis of late morbidity in men with diabetes mellitus","volume":"81","author":"Kalakota","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib44","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/bju.12969","article-title":"Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity","volume":"116","author":"Steinberger","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib45","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1200\/JCO.2006.07.9954","article-title":"Patient and treatment factors associated with complications after prostate brachytherapy","volume":"24","author":"Chen","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib46","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.prro.2014.09.004","article-title":"Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques","volume":"5","author":"Murphy","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib47","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.prro.2015.04.009","article-title":"High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment","volume":"5","author":"Fuller","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13014-017-0833-9","article-title":"Salvage robotic SBRT for local prostate cancer recurrence after radiotherapy: Preliminary results of the Oscar Lambret Center","volume":"12","author":"Leroy","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib49","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib50","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fonc.2016.00114","article-title":"Intensity-modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: The Georgetown University experience","volume":"6","author":"Mercado","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib51","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1186\/s12885-018-4511-6","article-title":"PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: The PROMETHEUS study protocol","volume":"18","author":"Richardson","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib52","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: Final results of a\u00a0phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib54","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.euo.2018.06.013","article-title":"Phase 2 Multicenter trial of heterogeneous-dosing stereotactic body radiotherapy for low- and intermediate-risk prostate cancer: 5-year outcomes","volume":"1","author":"Fuller","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib55","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: A systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib56","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1667\/RR2530.1","article-title":"Imaging radiation-induced normal tissue injury","volume":"177","author":"Robbins","year":"2012","journal-title":"Radiat Res"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib57","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijrobp.2013.10.042","article-title":"Impact of dose to the bladder trigone on long-term urinary function after high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"88","author":"Ghadjar","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2006.03.034","article-title":"Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: Normal tissue complication probability modeling","volume":"66","author":"Peeters","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.09.054_bib59","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1533034616649495","article-title":"Interfraction anatomical variability can lead to significantly increased rectal dose for patients undergoing stereotactic body radiotherapy for prostate cancer","volume":"16","author":"Wahl","year":"2017","journal-title":"Technol Cancer Res Treat"},{"issue":"3 Suppl","key":"10.1016\/j.ijrobp.2020.09.054_bib60","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.ijrobp.2009.08.074","article-title":"The lessons of QUANTEC: Recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome","volume":"76","author":"Jackson","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162034356X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162034356X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:53:20Z","timestamp":1759744400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162034356X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S036030162034356X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.09.054","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.09.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}